207 related articles for article (PubMed ID: 34344022)
21. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
22. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
[TBL] [Abstract][Full Text] [Related]
23. EZH2 and Endometrial Cancer Development: Insights from a Mouse Model.
Fang X; Ni N; Wang X; Tian Y; Ivanov I; Rijnkels M; Bayless KJ; Lydon JP; Li Q
Cells; 2022 Mar; 11(5):. PubMed ID: 35269532
[TBL] [Abstract][Full Text] [Related]
24. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
25. Enhancer of zeste homolog 2 (EZH2) regulates adipocyte lipid metabolism independent of adipogenic differentiation: Role of apolipoprotein E.
Yiew NKH; Greenway C; Zarzour A; Ahmadieh S; Goo B; Kim D; Benson TW; Ogbi M; Tang YL; Chen W; Stepp D; Patel V; Hilton R; Lu XY; Hui DY; Kim HW; Weintraub NL
J Biol Chem; 2019 May; 294(21):8577-8591. PubMed ID: 30971429
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.
Dudakovic A; Camilleri ET; Xu F; Riester SM; McGee-Lawrence ME; Bradley EW; Paradise CR; Lewallen EA; Thaler R; Deyle DR; Larson AN; Lewallen DG; Dietz AB; Stein GS; Montecino MA; Westendorf JJ; van Wijnen AJ
J Biol Chem; 2015 Nov; 290(46):27604-17. PubMed ID: 26424790
[TBL] [Abstract][Full Text] [Related]
27. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ
Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722
[TBL] [Abstract][Full Text] [Related]
29. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
30. Uterine epithelial cell proliferation and endometrial hyperplasia: evidence from a mouse model.
Gao Y; Li S; Li Q
Mol Hum Reprod; 2014 Aug; 20(8):776-86. PubMed ID: 24770950
[TBL] [Abstract][Full Text] [Related]
31. Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia.
Shi Y; Xu L; Tao M; Fang L; Lu J; Gu H; Ma S; Lin T; Wang Y; Bao W; Qiu A; Zhuang S; Liu N
Am J Physiol Renal Physiol; 2019 Mar; 316(3):F488-F505. PubMed ID: 30566000
[TBL] [Abstract][Full Text] [Related]
32. Enhancer of Zeste homolog 2 (EZH2) induces epithelial-mesenchymal transition in endometriosis.
Zhang Q; Dong P; Liu X; Sakuragi N; Guo SW
Sci Rep; 2017 Jul; 7(1):6804. PubMed ID: 28754964
[TBL] [Abstract][Full Text] [Related]
33. Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis.
Martin-Mateos R; De Assuncao TM; Arab JP; Jalan-Sakrikar N; Yaqoob U; Greuter T; Verma VK; Mathison AJ; Cao S; Lomberk G; Mathurin P; Urrutia R; Huebert RC; Shah VH
Cell Mol Gastroenterol Hepatol; 2019; 7(1):197-209. PubMed ID: 30539787
[TBL] [Abstract][Full Text] [Related]
34. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
Chen Q; Zheng PS; Yang WT
Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
36. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
[TBL] [Abstract][Full Text] [Related]
37. EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma.
Xue L; Yan H; Chen Y; Zhang Q; Xie X; Ding X; Wang X; Qian Z; Xiao F; Song Z; Wu Y; Peng Y; Xu H
BMC Cancer; 2019 Nov; 19(1):1094. PubMed ID: 31718595
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
39. Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22α expression in endothelial cells in response to interleukin-1β and transforming growth factor-β2.
Maleszewska M; Gjaltema RA; Krenning G; Harmsen MC
Cell Signal; 2015 Aug; 27(8):1589-96. PubMed ID: 25917318
[TBL] [Abstract][Full Text] [Related]
40. EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses' Health Studies.
Beca F; Kensler K; Glass B; Schnitt SJ; Tamimi RM; Beck AH
Breast Cancer Res; 2017 Mar; 19(1):21. PubMed ID: 28253895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]